Endogenous cannabinoids in liver disease: Many darts for a single target;Cannabinoides endógenos en la enfermedad hepática: muchos dardos para una sola diana

Gastroenterologia y Hepatologia

Volumn 33, Issue 4, 2010, Pages 323-329

  Reichenbach, Vedrana ^a   Ros, Josefa ^a   Jiménez, Wladimiro ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Anandamide; Endocannabinoids; Liver cirrhosis

Indexed keywords

ENDOCANNABINOID;

ARTICLE; DISEASE SEVERITY; FATTY LIVER; HEART DISEASE; HEART HEMODYNAMICS; HEPATIC ENCEPHALOPATHY; HUMAN; LIVER DISEASE; LIVER DYSFUNCTION; LIVER FIBROSIS; NEUROLOGIC DISEASE; NONHUMAN; OBESITY; PATHOGENESIS; PORTAL HYPERTENSION;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; APOPTOSIS; ASCITES; BLOOD PRESSURE; ENDOCANNABINOIDS; ENERGY METABOLISM; FATTY ACIDS; HEPATIC STELLATE CELLS; HUMANS; INFLAMMATION; LIVER CIRRHOSIS, EXPERIMENTAL; LIVER DISEASES; MICE; MONOCYTES; MYOCARDIAL CONTRACTION; OBESITY; RATS; RECEPTORS, CANNABINOID; SPLANCHNIC CIRCULATION; VASCULAR RESISTANCE;

EID: 77952884999     PISSN: 02105705     EISSN: 15789519     Source Type: Journal    
DOI: 10.1016/j.gastrohep.2009.06.010     Document Type: Article

References (48)

1. Arroyo V., Ginès P., Jiménez W., Rodés J. Renal dysfunction in cirrhosis. Oxford textbook of clinical hepatology 1999, 733-761. Oxford Medical Publications, Oxford, UK. 2 ed. J. Bircher, J.P. Benhamou, N. McIntire, M. Rizzetto, J. Rodés (Eds.).
2. Izzo A.A., Camilleri M. Emerging role of cannabinoids in gastrointestinal and liver diseases: Basic and clinical aspects. Gut 2008, 57:1140-1155.
3. Pacher P., Bátkai S., Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 2006, 58:389-462.
4. Jiménez W. Endocannabinoid and liver disease. Hepatology 2005, 41:983-985.
5. Lotersztajn S., Julien B., Teixera-Clerc F., Grenard P., Mallat A. Hepatic fibrosis: Molecular mechanisms and drug targets. Annu Rev Pharmacol Toxicol 2005, 45:605-628.
6. Kunos G., Osei-Hyiaman D. Endocannabinoids and liver disease. IV. Endocannabinoid involvement in obesity and hepatic steatosis. Am J Physiol 2008, 294:G1101-G1114.
7. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990, 346:561-564.
8. Munro S., Thomas K.L., Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993, 365:61-65.
9. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992, 258:1946-1949.
10. Di Marzo V., Bifulco M., De Petrocellis L. The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discovery 2004, 3:771-784.
11. Begg M., Pacher P., Bátkai S., Osei-Hyiaman D., Offertáler L., Mo F.M., et al. Evidence for novel cannabinoid receptors. Pharmacol Ther 2005, 106:133-145.
12. Ryberg E., Larsson N., Sjögren S., Hjorth S., Hermansson N.O., Leonova J., et al. The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 2007, 152:1092-1101.
13. Wagner J.A., Varga K., Ellis E.F., Rzigalinski B., Martin B.R., Kunos G. Activation of peripheral CB1 cannabinoid receptors in hemorrhagic shock. Nature 1997, 390:518-521.
14. Varga K., Wagner J.A., Bridgen D.T., Kunos G. Platelet- and macrophage derived endogenous cannabinoids are involved in endotoxic-induced hypotension. FASEB J 1998, 12:1035-1044.
15. Bátkai S., Jarai Z., Wagner J.A., Goparaju S.K., Varga K., Liu J., et al. Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis. Nat Med 2001, 7:827-832.
16. Ros J., Clària J., To-Figueras J., Planagumà A., Cejudo-Martín P., Fernández-Varo G., et al. Endogenous cannabinoids: A new system involved in the homeostasis of arterial pressure in experimental cirrhosis in the rat. Gastroenterology 2002, 122:85-93.
17. Biswas K.K., Sarker K.P., Abeyama K., Kawahara K., Iino S., Otsubo Y., et al. Membrane cholesterol but not putative receptors mediate anandamide-induced hepatocyte apoptosis. Hepatology 2003, 38:1167-1177.
18. Fernández-Rodríguez C.M., Romero J., Petros T.J., Bradshaw H., Gasalla J.M., Gutiérrez M.L., et al. Circulating endogenous cannabinoid anandamide and portal, systemic and renal hemodynamics in cirrhosis. Liver Int 2004, 24:477-483.
19. Domenicali M., Ros J., Fernández-Varo G., Cejudo-Martín P., Crespo M., Morales-Ruiz M., et al. Increased anandamide induced relaxation in mesenteric arteries of cirrhotic rats: Role of cannabinoid and vanilloid receptors. Gut 2005, 54:522-527.
20. Moezi L., Gaskari S.A., Liu H., Baik S.K., Dehpour A.R., Lee S.S. Anandamide mediates hyperdynamic circulation in cirrhotic rats via CB (1) and VR (1) receptors. Br J Pharmacol 2006, 149:898-908.
21. Domenicali M, Caraceni P, Giannone F, Pertosa AM, Principe A, Zambruni A, et al. Cannabinoid type 1 receptor antagonism delays ascites formation in rats with cirrhosis. Gastroenterology. 2009;137:341-9.
22. Blendis L., Wong F. Is there a cirrhotic cardiomyopathy?. Am J Gastroenterology 2000, 11:3026-3028.
23. Laffi G., Barletta G., La Villa G., Del Bene R., Riccardi D., Ticali P. Altered cardiovascular responsiveness to active tilting in non alcoholic cirrhosis. Gastroenterology 1997, 113:891-898.
24. Moller S., Sondergaard L., Mogelvang J., Henriksen O, Henriksen J.H. Decreased right heart blood volume determined by magnetic resonance imaging: Evidence of central underfilling in cirrhosis. Hepatology 1995, 22:472-478.
25. Kelbaek H., Eriksen J., Brynjolf I., Raboel A., Lund J.O., Munck O. Cardiac performance in patients with asymptomatic alcoholic cirrhosis of the liver. Am J Cardiol 1984, 54:852-855.
26. Ma Z., Lee S.S. Cirrhotic cardiomyopathy: Getting to the heart of the matter. Hepatology 1996, 24:451-459.
27. Pozzi M., Carugo S., Boari G., Pecci V., De Ceglia S., Maggolini S. Evidence of functional and structural cardiac abnormalities in cirrhotic patients with and without ascites. Hepatology 1997, 26:1131-1137.
28. Gaskari S.A., Liu H., Moezi L., Li Y., Baik S.K., Lee S.L. Role of endocannabinoids in the pathogenesis of cirrhotic cardiomyopathy in bile duct-ligated rats. Br J Pharmacol 2005, 146:315-323.
29. Ippolito S., Mani A.R., Moore K.P. Endogenous cannabinoids and cardiac dysfunction in cirrhosis. J Hepatol 2006, 44:S77.
30. Bátkai S., Mukhopadhyay P., Harvey-White J., Kechrid R., Pacher P., Kunos G. Endocannabinoids acting at CB1 receptors mediate the cardiac contractile dysfunction in vivo in cirrhotic rats. Am J Physiol 2007, 293:H1689-H1695.
31. Hézode C., Roudot-Thoraval F., Nguyen S., Grenard P., Julien B., Zafrani E.S., et al. Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C. Hepatology 2005, 42:63-71.
32. Siegmund S.V., Uchinami H., Osawa Y., Brenner D.A., Schwabe R.F. Anandamide induces necrosis in primary hepatic stellate cells. Hepatology 2005, 41:1085-1095.
33. Teixera-Clerc F., Julien B., Grenard P., Van Nhieu J.T., Deveaux V., Li L., et al. CB1 cannabinoid receptor antagonism: A new strategy for the treatment of liver fibrosis. Nat Med 2006, 12:671-676.
34. Julien B., Grenard P., Teixera-Clerc F., Van Nhieu J.T., Li L., Karsak M., et al. Antifibrotic role of the cannabinoid receptor CB2 in the liver. Gastroenterology 2005, 128:742-755.
35. Van Sickle M.D., Duncan M., Kingsley P.J., Mouihate A., Urbani P., Mackie K., et al. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 2005, 310:329-332.
36. Després J.P., Golay A., Sjöström L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005, 353:2121-2134. Rimonabant in Obesity-Lipids Study Group.
37. Muñoz-Luque J., Ros J., Fernández-Varo G., Tugues S., Morales-Ruiz M., Álvarez C.E., et al. Regression of fibrosis after chronic stimulation of cannabinoid CB2 receptor in cirrhotic rats. J Pharmacol Exp Ther 2008, 324:475-483.
38. Bátkai S., Osei-Hyiaman D., Pan H., El-Assal, Rajesh M., Mukhopadhyay P., et al. Cannabinoid-2 receptor mediates protection against hepatic ischemia/reperfusion injury. FASEB J 2007, 21:1788-1800.
39. Rajesh M., Pan H., Mukhopadhyay P., Bátkai S., Osei-Hyiaman, Haskó G., et al. Pivotal advance: Cannabinoid-2 receptor agonist HU-308 protects against hepatic ischemia/reperfusion injury by attenuating oxidative stress, inflammatory response and apoptosis. J Leukoc Biol 2007, 82:1382-1389.
40. Avraham Y., Israeli E., Gabbay E., Okun A., Zolotarev O., Silberman I., et al. Endocannabinoids affect neurological and cognitive function in thioacetamide-induced hepatic encephalopathy in mice. Neurobiol Dis 2006, 21:237-245.
41. Dagon Y., Avraham Y., Ilan Y., Mechoulam R., Berry E.M. Cannabinoids ameliorate cerebral dysfunction following liver failure via AMP-activated protein kinase. FASEB J 2007, 21:2431-2441.
42. Cota D., Marsicano G., Tschöp M., Grübler Y., Flachskamm C., Schubert M., et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 2003, 112:423-431.
43. Osei-Hyiaman D., DePetrillo M., Pacher P., Liu J., Radaeva S., Bátkai S., et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 2005, 115:1298-1305.
44. Osei-Hyiaman D., Liu J., Zhou L., Godlewski G., Harvey-White J., Jeong W.I., et al. Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice. J Clin Invest 2008, 118:3160-3169.
45. Hézode C., Zafrani E.S., Roudot-Thoraval F., Costentini C., Hessami A., Bouvier-Alias M., et al. Daily cannabis use: As a risk factor of steatosis severity in patients with chronic hepatitis C. Gastroenterology 2008, 134:432-439.
46. Méndez-Sánchez N., Zamora-Valdés D., Pichardo-Bahena R., Barredo-Prieto B., Ponciano-Rodríguez G., Bermejo-Martínez L., et al. Endocannabinoid receptor CB2 in nonalcoholic fatty liver disease. Liver Int 2007, 27:215-219.
47. Deveaux V., Ichigotani Y., Teixeira-Clerc F., Tran-Van-Nhieu J., Decaens T., Karzak M., et al. CB2 receptor antagonism reduces diet-induced obesity, insulin resistance and hepatic steatosis. PLOS 2009, 4:e5844.
48. Jeong W.I., Osei-Hyiaman D., Park O., Liu J., Bátkai S., Mukhopadhyay P., et al. Paracrine activation of hepatic CB1 receptors by stellate cell-derived endocannabinoids mediates alcoholic fatty liver. Cell Metab 2008, 7:227-235.